Evidence map›Paper›PMID 35277841›Full record

ArticlePharmaceutical research2022

A Mechanistic Understanding of Monoclonal Antibody Interfacial Protection by Hydrolytically Degraded Polysorbate 20 and 80 under IV Bag Conditions.

Aadithya Kannan, Jamie Giddings, Shrenik Mehta, Tiffany Lin, Anthony Tomlinson, Kyle Ritchie, Ian Shieh, Miguel Saggu, Nidhi Doshi

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Aadithya KannanPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Jamie GiddingsPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Shrenik MehtaPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Tiffany LinPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Anthony TomlinsonPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Kyle RitchiePharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Ian ShiehPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Miguel SagguPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Nidhi DoshiPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA. doshin1@gene.com.ORCID http://orcid.org/0000-0002-7553-1864
Genesys (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePolysorbates (PS) contain polyoxyethylene (POE) sorbitan/isosorbide fatty acid esters that can partially hydrolyze over time in liquid drug products to generate degradants and a remaining intact PS fraction with a modified ester distribution. The degradants are composed of free fatty acids (FFAs) --primarily lauric acid for PS20 and oleic acid for PS80-- and POE head groups. We previously demonstrated that under IV bag agitation conditions, mAb1 (a surface-active IgG4) aggregation increased with increasing amounts of degradants for PS20 but not for PS80. The purpose of this work is to understand the mechanism behind this observation.

methodsThe surface tension of the remaining intact PS fraction without degradants was modeled and compared with that of enzymatically degraded PS solutions. Next, mAb1 aggregation in saline was measured in the presence of laurate and oleate salts during static storage. Lastly, colloidal and conformational stability of mAb1 in the presence of these salts was investigated through differential scanning fluorimetry and dynamic light scattering under IV bag solution conditions.

resultsThe surface tension was primarily influenced by FFAs rather than the modified ester distribution of the remaining intact PS. MAb1 bulk aggregation increased in the presence of laurate but not oleate salts. Both salt types increased the melting temperature of mAb1 indicating FFA-mAb1 interactions. However, only laurate salt increased mAb1 self-association potentially explaining the higher aggregation propensity in its presence.

conclusionOur results help explain the observed differences between hydrolytically degraded PS20 and PS80 in affecting mAb1 aggregation under IV bag agitation conditions.

Indexed as

Antibodies, MonoclonalPolysorbatesEstersFatty Acids, NonesterifiedHydrolysisOleic AcidPolyethylene GlycolsSaltsSurface-Active AgentsAntibodies, MonoclonalEstersFatty Acids, NonesterifiedOleic AcidPolyethylene GlycolsPolysorbatesSaltsSurface-Active AgentsmAb aggregationpolysorbate degradationPS20, PS80surfactant

Identifiers

PMID35277841
OpenAlexW4220795876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.